155. Lancet and Statin in the Elderly

155. Lancet and Statin in the Elderly


https://www.clinicalkey.com/#!/content/journal/1-s2.0-S0140673620322339?scrollTo=%23hl0000424

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32233-9/fulltext

do statins work in old people?? This study in the lancet says-

“In a contemporary primary prevention cohort, people aged 70–100 years with elevated LDL cholesterol had the highest absolute risk of myocardial infarction and atherosclerotic cardiovascular disease and the lowest estimated NNT in 5 years to prevent one event.’

researchers calculated that 80 adults aged 80–100 years — would need to receive a moderate-intensity statin for 5 years to prevent one MI.
and145 adults aged 70–79 years — would need to receive a moderate-intensity statin for 5 years to prevent one MI.
and to prevent just one ASCVD event, the numbers needed to treat were 42 and 88, respectively.

But anytime you read the results you have to say “how did you come up with that number” what were your methods?

In this study they took a sample of people from a large Danish database and these were low risk individuals not on statin therapy. They calculated the number of reduced events by calculating the event rate they expected and dividing it by the number of events during the follow up.

But remember youi have to ask how did you come up with your calculation???

“For these calculations, we assumed 30% and 22% relative risk reduction of myocardial infarction and atherosclerotic cardiovascular disease, respectively, per 1·0 mmol/L reduction in LDL cholesterol in individuals free of atherosclerotic cardiovascular disease, as observed in the Cholesterol Trialist Collaboration meta-analyses.”

THIS IS FRUSTRATING because if you have read the cholesterol trialist you collaboration you know that the individuals in the studies were HONDA they were not low risk individuals. The higher the risk you are the more likely a drug is to work. Think about it like this a statin is more likely to work on someone who is really high risk because they are way more likely to have a MACE. Just like breast cancer chemo therapy is more likely to work on someone who has breast cancer and is even more likely to work if the person is a women.

So in this study they estimated the event rate based on really sick people and then said based on that we can say the likelihood for benefit in these more healthy patients would have a benefit or NNT of 42 or 80 to prevent just one MACE.

NOOOOO you cant take the odds of sick people or people with breast cancer and then say well look how it worked in them so it must work the same way in this population over here.


Do the trial of statins in the elderly or don’t publish the paper

Episoder(385)

Episode 294: 293. Should GLP-1 Agonist be Held Prior to Procedure or Surgery?

Episode 294: 293. Should GLP-1 Agonist be Held Prior to Procedure or Surgery?

glucagon-like peptide-1 (GLP-1) receptor agonists can delay gastric emptying, the American Society of Anesthesiologists (ASA) say For patients on daily dosing consider holding GLP-1 agonists on the da...

24 Mai 20245min

Episode 293: 292. An Antibiotic RCT for Community Acquired Pneumonia

Episode 293: 292. An Antibiotic RCT for Community Acquired Pneumonia

But now we have RCT data—278 adults with moderate CAP who were hospitalized (but not in intensive care) to receive either a β-lactam antimicrobial plus clarithromycin or a β-lactam alone. (all patient...

23 Mai 20244min

Episode 292: 291. Does CHATGPT Have a Career In Pathology?

Episode 292: 291. Does CHATGPT Have a Career In Pathology?

AI technology was highly accurate at identifying malignancies and tumor origins — as accurate as senior pathologists, and significantly more accurate than junior pathologists.   Patients with cancer o...

22 Mai 20245min

Episode 291: 290. When Should You Use IV Albumin?

Episode 291: 290. When Should You Use IV Albumin?

HERE IS WHEN IT IS RECOMMENDED TO USE ALBUMIN In patients with cirrhosis and spontaneous bacterial peritonitis, to substantially limit kidney impairment and mortality (low-certainty evidence) THIS IS ...

21 Mai 20246min

Episode 290: 289. Which GLP-1 is the Best Weight Loss Drug?

Episode 290: 289. Which GLP-1 is the Best Weight Loss Drug?

The results for weight loss was  Tirzepatide also known as mounjaro – 8.5 kg  Semaglutide also known as Ozempic -3.1 kg lost Liraglutide aka Victoza – 1.3 kg lostTirzepatide also known as mounjaro – 8...

20 Mai 20245min

Episode 289: 288. An RCT for Time Restricted Eating!

Episode 289: 288. An RCT for Time Restricted Eating!

41 adults (mean age, 59) with obesity (mean weight, 99 kg) and prediabetes or diet-controlled diabetes – everyone got the same diet. Same  micro- and macronutrient composition; same calorie amounts Fo...

17 Mai 20245min

Episode 288: 287. A New FDA Approved Drug for Chronic Rhinosinusitis

Episode 288: 287. A New FDA Approved Drug for Chronic Rhinosinusitis

recipients were more likely than placebo recipients to report much or very much improvement (55% vs. 25%) which isn’t shocking because half of the people were not getting medicinethey also report that...

16 Mai 20248min

Episode 287: 286. Does Hypokalemia cause Heart Badness?

Episode 287: 286. Does Hypokalemia cause Heart Badness?

https://onlinelibrary.wiley.com/doi/10.1111/joim.13757ECG abnormalities were present in 40% of hypokalemic patients and included t-wave flattening/inversion, ST-segment depression, QTc prolongation, l...

15 Mai 20245min

Populært innen Helse

fastlegen
rss-gukild-johaug
hvordan-har-du-det-mann
lydartikler-fra-aftenposten
psykodrama
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-garne-damer
foreldreradet
hormonelle-frida
morten-ramm-lar-kakla-ga-til-du-sovner
rss-lopedrommen
hjernesterk
klimaks
g-punktet
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
hverdagspsyken
treningsprat
helsetipspodden
kjed-deg-i-sovn-verdens-kjedeligste-podcast